Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts;
Christine M. Mauro
Mailman School of Public Health, Columbia University
Xin Qiu
Mailman School of Public Health, Columbia University
Natalia A. Skritskaya
Columbia School of Social Work, New York, New York
Charles F. Reynolds III
Geriatric Psychiatry and Graduate School of Public Health, University of Pittsburgh School of Medicine
Sidney Zisook
Department of Psychiatry, University of California, San Diego
M. Katherine Shear
Columbia School of Social Work, New York, New York, and Department of Psychiatry, Columbia University College of Physicians and Surgeons
Naomi M. Simon
Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, and Department of Psychiatry, Harvard Medical School
Acknowledgement: Naomi M. Simon is now at the Department of Psychiatry, New York University.
This work was supported by a grant from the National Institute of Mental Health: R01MH085297 and a grant from the American Foundation for Suicide Prevention: LSRG-S-172-12. Naomi M. Simon has received research support from the American Foundation for Suicide Prevention, Department of Defense, Highland Street Foundation, and NIH. Her spouse has equity in G1 Therapeutics.
Nonspecific treatment factors, including outcome expectancy (
Outcome expectancy, or a patient’s expectation for improvement as a result of participating in treatment (
Working alliance refers to the quality of the therapist–patient relationship, usually measured in a way which encompasses the personal bond along with the mutual agreement about treatment goals and how best to achieve them (
The impact of expectancy and working alliance on pharmacotherapy treatment outcomes in individuals with complicated grief (CG) has not been previously examined. Initial studies suggested that pharmacological interventions, specifically antidepressant medications, had promise in treating CG (
The present study was a secondary analysis of a multisite, double-blind, randomized, controlled trial (RCT) examining the efficacy of an antidepressant medication, the serotonin selective reuptake inhibitor (SSRI) citalopram, alone or in combination with CGT for adults with CG. We were interested in examining the relationship between both pretreatment pharmacotherapy expectancy and working alliance with the pharmacotherapist on CG symptom improvement and dropout from treatment. Participants were recruited at four academic medical centers and randomized to one of four treatment conditions: citalopram (CIT), pill placebo (PBO), CGT + citalopram (CGT + CIT), or CGT + placebo (CGT + PBO). In the original study, controlling for site variation, response rates were higher for CGT + PBO (83%) than PBO (55%) and CGT + CIT (84%) than CIT (69%), and showed equivalent results for CGT + CIT and CGT + PBO. The purpose of this secondary analysis was to determine whether treatment expectancies and the therapeutic alliance might account for pharmacotherapy not being as effective as it was when delivered in combination with CGT. We were interested in whether adding CGT to medication or placebo was associated with higher expectancies for pharmacotherapy and higher alliance scores with pharmacotherapists, perhaps because participants viewed stand-alone medication treatment for grief as less effective than medication delivered in combination with psychotherapy. We hypothesized that (a) participants receiving medication without CGT would report lower expectancies for medication treatment response than participants assigned to CGT, (b) participants who endorsed greater expectancy and working alliance would demonstrate lower dropout rates, and (c) participants who endorsed higher expectancy and alliance would demonstrate greater treatment response later regardless of treatment assignment. As an exploratory analysis, we were interested in examining whether CGT assignment status moderated the relationship between treatment expectancy and working alliance and outcome.
Full details regarding the methodology can be found in the report of primary outcomes (
After baseline assessment, participants were assigned to protocolized pharmacotherapy with flexible dosing. The pharmacotherapists (n = 19) were primarily psychiatrists (89%) with one PharmD and one RN who were knowledgeable about CG. Pharmacotherapy included emphasis on a clear rationale for treatment using antidepressant medication, building a strong therapeutic alliance, psychoeducation about CG and medication use, and provision of support. Those randomized to CGT were also assigned a psychotherapist. Participants completed follow-up assessments at 4, 8, 12, 16, and 20 weeks after the first treatment visit and 6 months after study termination. All measures were completed at each assessment period, with the exception of the outcome expectancy and working alliance measures which were completed at the second treatment visit in Week 2. Outcomes were examined at Week 12 as this time was the primary pharmacotherapy outcome assessment in the parent study.
Clinician Global Impressions—Improvement and Severity of Illness (CGI-I, CGI-S)
Treatment response was defined as a rating of 1 (very much) or 2 (much) improved on the CGI-I. The CGI-I and CGI-S (
ICG
The ICG (
Treatment outcome expectancy
This is a widely adapted measure designed to assess the patient’s perceived credibility of the treatment (
Working Alliance Inventory-Short Form (WAI-SF)
The WAI-SF (
Descriptive statistics for continuous variables are reported as means and SDs. Categorical variables are reported as frequencies and distributions. Demographic and clinical variables at baseline were compared between patients who completed measures of expectancy and working alliance and patients who did not, using chi-squared tests for categorical variables and two-sample t tests for continuous variables. Consistent with the parent study, the same statistical approaches were used to compare treatment expectancy and working alliance between treatment responders (CGI-I = “much” or “very much improved”) and nonresponders (all other CGI-I ratings), as well as between medication treatment completers and those who dropped before week 12. To assess whether the relationships between expectancy and outcome and alliance on outcome varied by CGT status, stratified analyses were performed. Statistical significance was defined using a two-tailed α = .05. Data were analyzed using SAS 9.3.
Participants were mostly female (75%), White (81%), and had completed college (57%). The mean age was 51.51 years (SD = 13.59). Relation to the deceased varied and included partner (36%), parent (34%), child (16%), and friend or other relative (14%). Average time since loss was 4.77 years (SD = 6.47). There were no differences between the study sample and those who were excluded in age (p = .98), gender (p = .47), race (p = .65), education (p = .18), marital status (p = .61), relationship to the deceased (p = .21), time since loss (p = .49), or CG symptom severity (p = .77). Those not included in this analysis because they did not complete the expectancy and alliance forms were more likely to drop out (63% vs. 24%, χ
Descriptive statistics for outcomes, expectancy, and working alliance are presented in
Evidence was mixed with respect to our second hypothesis. Expectancy was lower among those who dropped out of pharmacotherapy (n = 49: M = 15.41, SD = 6.60) compared with those who were still in treatment (n = 153: M = 20.10, SD = 5.43), t(200) = 4.99, p < .0001, Cohen’s d = 0.82. However, there was no evidence of a difference in working alliance between those who dropped out of pharmacotherapy (n = 49: M = 61.65, SD = 13.28) and those who did not drop out (n = 153: M = 65.12, SD = 12.85), t(200) = 1.63, p = .105, Cohen’s d = 0.27.
Evidence was mixed with respect to our third hypothesis. Expectancy was higher among those who responded to treatment (n = 94: M = 20.79, SD = 5.15) compared with those who did not (n = 76: M = 17.47, SD = 6.26), t(168) = 3.79, p < .001, Cohen’s d = 0.58. Contrary to expectation, there was no evidence of a difference in working alliance for those who responded to treatment (n = 94: M = 65.38, SD = 12.31) and those who did not (n = 76: M = 62.57, SD = 14.40), t(168) = 1.37, p = .17, Cohen’s d = 0.21.
The results of our exploratory hypothesis suggested that assignment to CGT did not modify the relationship between expectancy or alliance on any of the outcomes examined with one exception. Among participants receiving CGT, working alliance was significantly lower among those who dropped out of pharmacotherapy (n = 25: M = 64.68, SD = 11.08) compared with those who did not (n = 85: M = 69.56, SD = 9.54), t(108) = 2.17, p < .05, Cohen’s d = 0.49.
In this secondary analysis of a multisite RCT, randomization to concurrent CGT, a targeted psychotherapy for CG, was associated with higher expectations for medication treatment and higher working alliance with the pharmacotherapist. Consistent with our hypothesis, higher outcome expectancy early in treatment was associated with better outcomes and lower dropout from pharmacotherapy. In contrast, working alliance was not associated with treatment outcomes regardless of treatment assignment, with the exception of those receiving CGT and medication for whom lower alliance was associated with higher pharmacotherapy drop out. These findings, which suggest that grief symptom reductions are more likely to occur in the context of positive expectations for treatment than positive regard for the pharmacotherapist, support the expectancy theory, which may explain the placebo effect (
Randomization to CGT further enhanced positive expectations about medication effectiveness, underscoring the importance of psychosocial treatments in the intervention of CG. Participants’ expectations were perhaps bolstered by having multiple providers, exposure to multiple interventions, or because of a belief that medication outcomes will be better when given the opportunity to address grief in psychotherapy. Patients may prefer a structured-grief-focused psychotherapy over medication alone, even if the latter is delivered with extra support from the prescriber (as was the case in this study). Although treatment preference was not systematically assessed in the current study, anecdotally we observed that many participants had preferences for CGT. Having preference for therapy, and then being randomly assigned to a pharmacotherapy only arm of treatment, may have attenuated outcome expectations for this subsample and may explain the relationship between dropout and noncompletion of alliance and expectancy measures. Although preference is distinct from treatment expectancy, preference is known to influence both expectancy and alliance (
There are several limitations. First, our sample was limited to individuals participating in a RCT, which limits generalizability to adults seeking treatment for CG in real-world settings. Second, we did not measure symptom change between baseline and Week 2 of the study. An alternative explanation of our findings is that early symptom change led to differences in outcome expectancy and alliance at Week 2. Third, neither expectancy and working alliance nor CG severity were measured in an ongoing manner (session-by-session) throughout treatment. Evidence suggests that working alliance strengthens as treatment progresses (
In working with patients with CG, pharmacotherapists are encouraged to make explicit efforts to increase outcome expectancy and provide opportunity for involvement in evidence-based, grief-focused psychotherapy.
Arnow, B. A., Steidtmann, D., Blasey, C., Manber, R., Constantino, M. J., Klein, D. N., . . .Kocsis, J. H. (2013). The relationship between the therapeutic alliance and treatment outcome in two distinct psychotherapies for chronic depression. Journal of Consulting and Clinical Psychology, 81, 627–638. 10.1037/a0031530
Asay, T. P., & Lambert, M. J. (1999). The empirical case for the common factors in therapy: Quantitative findings. In M. A.Hubble, B. L.Duncan, & S. D.Miller (Eds.), The heart and soul of change: What works in therapy (pp. 23–56). Washington, DC: American Psychological Association. 10.1037/11132-001
Baldwin, S. A., Wampold, B. E., & Imel, Z. E. (2007). Untangling the alliance-outcome correlation: Exploring the relative importance of therapist and patient variability in the alliance. Journal of Consulting and Clinical Psychology, 75, 842–852. 10.1037/0022-006X.75.6.842
Barber, J. P., Zilcha-Mano, S., Gallop, R., Barrett, M., McCarthy, K. S., & Dinger, U. (2014). The associations among improvement and alliance expectations, alliance during treatment, and treatment outcome for major depressive disorder. Psychotherapy Research, 24, 257–268. 10.1080/10503307.2013.871080
Barth, R. P., Lee, B. R., Lindsey, M. A., Collins, K. S., Strieder, F., Chorpita, B. F., . . .Sparks, J. A. (2012). Evidence-based practice at a crossroads: The timely emergence of common elements and common factors. Research on Social Work Practice, 22, 108–119. 10.1177/1049731511408440
Borkovec, T. D., & Nau, S. D. (1972). Credibility of analogue therapy rationales. Journal of Behavior Therapy and Experimental Psychiatry, 3, 257–260. 10.1016/0005-7916(72)90045-6
Busseri, M. A., & Tyler, J. D. (2003). Interchangeability of the Working Alliance Inventory and Working Alliance Inventory, Short Form. Psychological Assessment, 15, 193–197. 10.1037/1040-3590.15.2.193
Constantino, M. J., Arnkoff, D. B., Glass, C. R., Ametrano, R. M., & Smith, J. Z. (2011). Expectations. Journal of Clinical Psychology, 67, 184–192. 10.1002/jclp.20754
Devilly, G. J., & Borkovec, T. D. (2000). Psychometric properties of the credibility/expectancy questionnaire. Journal of Behavior Therapy and Experimental Psychiatry, 31, 73–86. 10.1016/S0005-7916(00)00012-4
Greenberg, R. P., Constantino, M. J., & Bruce, N. (2006). Are patient expectations still relevant for psychotherapy process and outcome?Clinical Psychology Review, 26, 657–678. 10.1016/j.cpr.2005.03.002
Guy, W. (1970). Clinical global impression: Manual for the ECDEU Assessment Battery. Washington, DC: National Institute of Mental Health.
Hensley, P. L., Slonimski, C. K., Uhlenhuth, E. H., & Clayton, P. J. (2009). Escitalopram: An open-label study of bereavement-related depression and grief. Journal of Affective Disorders, 113, 142–149. 10.1016/j.jad.2008.05.016
Holt, C. S., & Heimberg, R. G. (1990). The Reaction to Treatment Questionnaire: Measuring treatment credibility and outcome expectations. Behavior Therapist, 13, 213–214, 222.
Kim, S. Y., & Holloway, R. G. (2003). Burdens and benefits of placebos in antidepressant clinical trials: A decision and cost-effectiveness analysis. The American Journal of Psychiatry, 160, 1272–1276. 10.1176/appi.ajp.160.7.1272
Kirsch, I. (1997). Specificying nonspecifics: Psychological mechanisms of placebo effects. In A.Harrington (Ed.), The placebo effect: An interdisciplinary exploration (pp. 166–186). Cambridge, MA: Harvard University Press.
Lambert, M. J., & Barley, D. E. (2001). Research summary on the therapeutic relationship and psychotherapy outcome. Psychotherapy: Theory, Research, & Practice, 38, 357–361. 10.1037/0033-3204.38.4.357
Le, Q. A., Doctor, J. N., Zoellner, L. A., & Feeny, N. C. (2014). Cost-effectiveness of prolonged exposure therapy versus pharmacotherapy and treatment choice in posttraumatic stress disorder (the Optimizing PTSD Treatment Trial): A doubly randomized preference trial. The Journal of Clinical Psychiatry, 75, 222–230. 10.4088/JCP.13m08719
Mergl, R., Henkel, V., Allgaier, A. K., Kramer, D., Hautzinger, M., Kohnen, R., . . .Hegerl, U. (2011). Are treatment preferences relevant in response to serotonergic antidepressants and cognitive-behavioral therapy in depressed primary care patients? Results from a randomized controlled trial including a patients’ choice arm. Psychotherapy and Psychosomatics, 80, 39–47. 10.1159/000318772
Prigerson, H. G., Maciejewski, P. K., Reynolds, C. F., III, Bierhals, A. J., Newsom, J. T., Fasiczka, A., . . .Miller, M. (1995). Inventory of Complicated Grief: A scale to measure maladaptive symptoms of loss. Psychiatry Research, 59, 65–79. 10.1016/0165-1781(95)02757-2
Rodebaugh, T. L., Holaway, R. M., & Heimberg, R. G. (2004). The treatment of social anxiety disorder. Clinical Psychology Review, 24, 883–908. 10.1016/j.cpr.2004.07.007
Rutherford, B. R., Wager, T. D., & Roose, S. P. (2010). Expectancy and the treatment of depression: A review of experimental methodology and effects on patient outcome. Current Psychiatry Reviews, 6, 1–10. 10.2174/157340010790596571
Rutherford, B. R., Wall, M. M., Brown, P. J., Choo, T. H., Wager, T. D., Peterson, B. S., Roose, S. P. (2017). Patient expectancy as a mediator of placebo effects in antidepressant clinical trials. American Journal of Psychiatry, 174, 135–142. 10.1176/appi.ajp.2016.16020225
Shear, M. K., Reynolds, C. F., III, Simon, N. M., Zisook, S., Wang, Y., Mauro, C., . . .Skritskaya, N. (2016). Optimizing treatment of complicated grief: A multicenter randomized clinical trial. Journal of the American Medical Association Psychiatry, 73, 685–694. 10.1001/jamapsychiatry.2016.0892
Tracey, T. J., & Kokotovic, A. M. (1989). Factor structure of the Working Alliance Inventory. Psychological Assessment, 1, 207–210. 10.1037/1040-3590.1.3.207
Submitted: November 7, 2016 Revised: December 11, 2017 Accepted: January 19, 2018